Hematology prior authorization at Priority Health
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Priority Health hematology PA at a glance
Priority Health reviews hematology PA submissions against its medical policy library, with rules drawn primarily from NCCN + ASH (American Society of Hematology). Priority Health-specific context: Subsidiary of Corewell Health (Michigan integrated health system, formed from Beaumont + Spectrum 2022); ~1.3M members. Second-largest insurer in Michigan after BCBS Michigan. Michigan DIFS oversight.
Documentation packet — what to send
- Diagnosis with ICD-10 (CLL, MM, NHL, etc.)
- Stage / risk stratification
- Molecular markers (BCR-ABL, TP53, IGHV, FISH)
- Prior lines of therapy with response
- Performance status
Common denial patterns to pre-empt
Patterns observed in hematology across payers, and where Priority Health's book of business overlaps:
- Off-label use (e.g., rituximab for non-Hodgkin's vs autoimmune)
- Indication-specific dosing
- Genetic testing (BCR-ABL, BRAF, TP53) not documented
- Step therapy in CLL / lymphoma
- Site of service for infusion
- Step therapy on specialty drugs
- Medicare Advantage Part B drug step therapy
Appeal angles when Priority Health denies
- NCCN Compendium citation for hematologic malignancy
- Molecular / cytogenetic test results supporting indication
- Performance status documentation
- Documented response/failure of prior lines
Peer-to-peer prep
- Bring the molecular pathology report
- Quote NCCN Compendium category (1, 2A, 2B)
- Reference the pivotal trial for the prescribed regimen
- Document prior-line response (CR, PR, SD, PD) explicitly
Drug-specific PA criteria at Priority Health
Deep dives on each drug's PA criteria at Priority Health:
Frequently asked questions
What documentation does Priority Health need for hematology prior authorizations?
Priority Health's PA packet for hematology typically includes: Diagnosis with ICD-10 (CLL, MM, NHL, etc.); Stage / risk stratification; Molecular markers (BCR-ABL, TP53, IGHV, FISH); Prior lines of therapy with response. NCCN + ASH (American Society of Hematology) citations strengthen the submission.
What's the turnaround at Priority Health?
Priority Health standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which hematology drugs does Priority Health most often PA-restrict?
Top targets in hematology: rituximab, imatinib, ibrutinib, lenalidomide, apixaban. Each follows the per-drug step therapy + documentation requirements published in Priority Health's medical policy library.
How do I prep a peer-to-peer with Priority Health in hematology?
Bring the molecular pathology report Quote NCCN Compendium category (1, 2A, 2B) Have the policy URL and the patient's chart open before the call.
Generate a Hematology PA packet
Open ApprovalHelp — generate a hematology PA packet tailored to Priority Health's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com